Physician profile
Eric S Jackson
NPI 1245317429
$8,521.17
in general payments reported to CMS, 2019-2025
48 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $322 · 2021: $483 · 2022: $1,167 · 2023: $1,492 · 2024: $1,044 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715 · Consulting Fee: $1,138 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.45 |
| Consulting Fee | $1,137.50 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $1,137.50 | 2025 | S-217622 |
| Otsuka America Pharmaceutical, INC. | $1,060.56 | 2019-2025 | Rexulti |
| Abbvie INC. | $910.77 | 2021-2025 | |
| Novo Nordisk INC | $762.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $634.38 | 2019-2024 | Prolia, Evenity, Otezla |
| Glaxosmithkline, LLC. | $523.02 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $494.42 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $406.35 | 2019-2024 | Verquvo, Belsomra, Gardasil 9 |
| Astrazeneca Pharmaceuticals Lp | $277.20 | 2019-2022 | |
| Axsome Therapeutics, INC. | $223.07 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $183.12 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.45 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $145.77 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $137.81 | 2019-2023 | Airduo Digihaler |
| Takeda Pharmaceuticals U.S.A., INC. | $126.35 | 2019-2024 | Trintellix |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.